As one of the world’s most influential academic events in oncology, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago, USA, from May 29 to June 2, 2026. The conference will bring together leading oncologists, clinicians, and researchers from around the world to discuss cutting-edge developments in precision oncology, innovative drug development, cellular immunotherapy, and comprehensive patient management, while exploring new evidence, treatment strategies, and future directions in cancer care.

Facing the complex challenges of malignant tumors and immune-related diseases, the GoBroad physician team has consistently remained patient-centered and clinically driven, continuously translating innovative therapies from research into real-world practice. At this year’s ASCO Annual Meeting, the GoBroad physician team will present eight research achievements, highlighting GoBroad’s clinical exploration and innovation in precision oncology, cellular immunotherapy, transplant bridging strategies, and comprehensive patient care.

Oral Presentations

Abstract No. 3505

Title: Phase 3 trial of trastuzumab rezetecan vs standard of care (SOC) for chemotherapy-refractory, HER2-positive, advanced colorectal cancer (CRC)

Presenter: Jin Li (Corresponding Author)

Institution: Shanghai GoBroad Cancer Hospital

Abstract No. 7015

Title: First-in-human novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies

Presenter: Haiyang Lu1

Corresponding Authors: Jing Pan2, Xiaoxia Hu1

Institutions:

1. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
2. Beijing GoBroad Hospital

Poster Presentations

Abstract No. 5532

Title: GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study

Authors: Pin Wang1, Haifeng Qin2, and 18 additional investigators from collaborating institutions
Institutions:

1. University of Southern California, USA
2. Beijing GoBroad Hospital

Abstract No. 6556

Title: Pre-transplant MRD negativity and TP53 mutation status determine survival after CAR-T therapy bridged to allo-HSCT for refractory/relapse B-ALL

First Author: Zhihui Li

Corresponding Author: Tong Wu

Institution: Beijing GoBroad Boren Hospital

Abstract No. 7021

Title: Overcoming resistance to prior CAR-T therapy: Efficacy and safety of a sequential, multi-antigen targeted CAR T-cell strategy in B-cell NHL

First Author: Guoai Su

Corresponding Author: Yajing Zhang

Institution: Beijing GoBroad Boren Hospital

ePoster Presentations

Abstract No. e13544

Title: Construction of a whole-course psychological nursing model and its impact on compliance with innovative drug therapy in patients with thoracic tumors: A prospective randomized controlled study

First Author: Liping Li

Corresponding Author: Haifeng Qin

Institution: Beijing GoBroad Hospital

Abstract No. e19017

Title: Antigen-switch and BCR-axis–enriched multi-target CAR T re-infusion after prior CAR T failure in R/R B-cell NHL

First Author: Peihao Zheng

Corresponding Author: Yajing Zhang

Institution: Beijing GoBroad Boren Hospital

Abstract No. e21506

Title: NICE-TIL (NKG2D-CAR/mbIL15/tEGFR-transduced TILs) and antitumor activity via dual TCR-HLA and NKG2D-NKG2DL killing pathways

First Author & Corresponding Author: Haifeng Qin

Institution: Beijing GoBroad Hospital

From cancer immunotherapy to cellular therapies for autoimmune diseases, and from innovative drug development to comprehensive patient support, the GoBroad physician team continues to address unmet clinical needs through systematic research and innovation. Moving forward, GoBroad will remain committed to patient-centered care and research-driven development, accelerating the translation of innovative therapies into clinical practice and bringing more patients the possibility of long-term survival and improved quality of life.

*Abstracts are listed according to abstract number order.